Oncolytic virotherapy (OV) CF33: CF33 is a proprietary OV that selectively infects and replicates within cancer cells, while sparing healthy cells. CF33 is currently in Phase 2 clinical trials for the treatment of gastric cancer and head and neck cancer.
Oncolytic virotherapy (OV) VAXINIA: VAXINIA is a proprietary OV that is being developed for the treatment of solid tumors. VAXINIA is currently in Phase 1 clinical trials for the treatment of non-small cell lung cancer.
Oncolytic virotherapy (OV) HER-V: HER-V is a proprietary OV that is being developed for the treatment of breast and gastric cancers. HER-V is currently in Phase 1 clinical trials.
T-cell receptor (TCR) therapy targeting NY-ESO-1: Imugene's TCR therapy targeting NY-ESO-1 is being developed for the treatment of a variety of solid tumors that express NY-ESO-1. Imugene's TCR therapy targeting NY-ESO-1 is currently in Phase 1 clinical trials.
Personalized cancer vaccines: Imugene is developing personalized cancer vaccines that are designed to induce an immune response against the patient's own tumor. Imugene's personalized cancer vaccines are currently in preclinical development.
CAR T-cell therapy: Imugene is developing a CAR T-cell therapy for the treatment of B-cell lymphoma. Imugene's CAR T-cell therapy is currently in preclinical development.
